Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tobramycin

FDA-approved product (solution/drops, ophthalmic), marketed as Aktob, Bethkis, Kitabis Pak and 8 more.

Registered studies
50+
Lab records
48
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tobramycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Bacterial disease
  • Cystic fibrosis
  • Eye infection
  • Infection
  • Inflammation
  • Respiratory tract infectious disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other aminoglycosides; Antibiotics
FDA pharmacologic class
Aminoglycoside Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB01; WHO ATC S01AA12; FDA class Aminoglycoside Antibacterial

Repurposing investigation

Tobramycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA4.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 3 of 10 lab records
  • E. coli: measured active in 6 of 15 lab records
  • K. pneumoniae: measured active in 17 of 23 lab records
Open Tobramycin in ChEMBL Registered studies below
Show the 48 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tobramycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study

    NCT00399945 · start 2006-05

    Registered record
    Registry ID
    NCT00399945
    Conditions
    Cystic Fibrosis
    Interventions
    Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-05
    Completion
    Not recorded
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTobramycin
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis

    NCT00391976 · start 2003-11

    Registered record
    Registry ID
    NCT00391976
    Conditions
    Cystic Fibrosis
    Interventions
    Tobramycin solution for inhalation 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-11
    Completion
    2008-01
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTobramycin solution for inhalation 300 mg
    PhasePhase 3
    Registry statusCompleted

  • UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

    NCT00083551 · start 1998-08

    Registered record
    Registry ID
    NCT00083551
    Conditions
    Multiple Myeloma
    Interventions
    Thalidomide; Ara-C; BCNU; Cisplatin; Cytoxan; Dexamethasone; Doxorubicin; Etoposide; Filgrastim; Recombinant GM-CSF; Interferon-alpha-2b; Melphalan; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-08
    Completion
    2014-08
    Enrolment
    668

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionThalidomide; Ara-C; BCNU; Cisplatin +9 more
    PhasePhase 3
    Registry statusCompleted

  • Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment

    NCT01559753 · start 1998-01

    Registered record
    Registry ID
    NCT01559753
    Conditions
    Pneumonia Ventilator Associated
    Interventions
    Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; compare 8 to15 days of antibiotic treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1998-01
    Completion
    2002-11
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia Ventilator Associated
    InterventionAugmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; compare 8 to15 days of antibiotic treatment
    PhasePhase 4
    Registry statusCompleted

  • The Effectiveness of Antibiotic Cement (ABC) Compared to Regular Cement in Reducing the Rate of Infection Following Total Knee Arthroplasty: The ABC Trial

    NCT01079559

    Registered record
    Registry ID
    NCT01079559
    Conditions
    Infection; Osteoarthritis of the Knee
    Interventions
    Simplex™ P with Tobramycin; Simplex™ P
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Osteoarthritis of the Knee
    InterventionSimplex™ P with Tobramycin; Simplex™ P
    PhasePhase 3
    Registry statusWithdrawn